We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Celldex Therapeutics (CLDX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics is a member of our Medical group, which includes 914 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Celldex Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLDX's full-year earnings has moved 10.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CLDX has gained about 30.4% so far this year. Meanwhile, stocks in the Medical group have lost about 0.1% on average. This shows that Celldex Therapeutics is outperforming its peers so far this year.
Another stock in the Medical sector, Illumina (ILMN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 50.1%.
Over the past three months, Illumina's consensus EPS estimate for the current year has increased 1.8%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Celldex Therapeutics belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #91 in the Zacks Industry Rank. On average, this group has gained an average of 2% so far this year, meaning that CLDX is performing better in terms of year-to-date returns. Illumina is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Celldex Therapeutics and Illumina as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Celldex Therapeutics (CLDX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics is a member of our Medical group, which includes 914 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Celldex Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLDX's full-year earnings has moved 10.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CLDX has gained about 30.4% so far this year. Meanwhile, stocks in the Medical group have lost about 0.1% on average. This shows that Celldex Therapeutics is outperforming its peers so far this year.
Another stock in the Medical sector, Illumina (ILMN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 50.1%.
Over the past three months, Illumina's consensus EPS estimate for the current year has increased 1.8%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Celldex Therapeutics belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #91 in the Zacks Industry Rank. On average, this group has gained an average of 2% so far this year, meaning that CLDX is performing better in terms of year-to-date returns. Illumina is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Celldex Therapeutics and Illumina as they attempt to continue their solid performance.